[{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"d1c65fef-f151-4887-8cfe-4cca4bc9b521","acronym":"","url":"https://clinicaltrials.gov/study/NCT03282396","created_at":"2021-01-18T16:12:27.906Z","updated_at":"2024-07-02T16:35:08.356Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma","source_id_and_acronym":"NCT03282396","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-04-22"},{"id":"1ba19375-a278-4a1e-94fc-7fcdc21b85ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05100251","created_at":"2021-10-29T13:53:09.517Z","updated_at":"2024-07-02T16:35:57.046Z","phase":"Phase 1","brief_title":"Clinical Trial of WB100 on Advanced Solid Tumor","source_id_and_acronym":"NCT05100251","lead_sponsor":"Zhejiang University","biomarkers":" MYC • CA 19-9","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC positive","tags":["MYC • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WB100"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 10/25/2023","primary_completion_date":" 10/25/2023","study_txt":" Completion: 10/25/2023","study_completion_date":" 10/25/2023","last_update_posted":"2023-01-26"},{"id":"396316cf-b663-4dd0-81ce-d6e47945f737","acronym":"","url":"https://clinicaltrials.gov/study/NCT01897012","created_at":"2021-01-18T08:30:51.764Z","updated_at":"2024-07-02T16:37:03.460Z","phase":"Phase 1","brief_title":"Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas","source_id_and_acronym":"NCT01897012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC positive","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/17/2013","start_date":" 07/17/2013","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 11/30/2018","study_completion_date":" 11/30/2018","last_update_posted":"2019-01-28"},{"id":"55236ebb-d5b0-4ba1-a8c6-67173aff7b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00765245","created_at":"2021-01-18T02:53:25.183Z","updated_at":"2024-07-02T16:37:32.859Z","phase":"Phase 2","brief_title":"Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00765245","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" MYC","pipe":" | ","alterations":" MYC positive","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2016-04-11"}]